Lifecore Biomedical (NASDAQ:LFCR – Get Free Report) and Theravance Biopharma (NASDAQ:TBPH – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.
Insider and Institutional Ownership
83.4% of Lifecore Biomedical shares are owned by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are owned by institutional investors. 32.7% of Lifecore Biomedical shares are owned by insiders. Comparatively, 7.6% of Theravance Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Analyst Recommendations
This is a summary of recent recommendations for Lifecore Biomedical and Theravance Biopharma, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lifecore Biomedical | 1 | 4 | 0 | 0 | 1.80 |
| Theravance Biopharma | 0 | 8 | 0 | 0 | 2.00 |
Valuation & Earnings
This table compares Lifecore Biomedical and Theravance Biopharma”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lifecore Biomedical | $128.87 million | 1.89 | -$40.50 million | ($1.07) | -6.02 |
| Theravance Biopharma | $104.31 million | 8.48 | $105.89 million | $1.01 | 16.86 |
Theravance Biopharma has lower revenue, but higher earnings than Lifecore Biomedical. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Lifecore Biomedical has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, Theravance Biopharma has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500.
Profitability
This table compares Lifecore Biomedical and Theravance Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lifecore Biomedical | -29.93% | N/A | -16.16% |
| Theravance Biopharma | 51.58% | -0.77% | -0.46% |
Summary
Theravance Biopharma beats Lifecore Biomedical on 9 of the 13 factors compared between the two stocks.
About Lifecore Biomedical
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
About Theravance Biopharma
Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs.
Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY.
For more information, please visit www.theravance.com.
Receive News & Ratings for Lifecore Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lifecore Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.
